Inovio Pharma(INO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.1100
Day High1.1500
Open:1.1300
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
MarketBeat
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
MarketBeat.com
Tipranks
Inovio Shareholders Endorse Governance Changes and Leadership
Tipranks
Inovio’s INO‑3107 Nears PDUFA Amid Cash Squeeze
Tipranks
Inovio Pharmaceuticals Earnings Call: Progress Amid Cash Strain
Motley Fool
Inovio (INO) Q1 2026 Earnings Call Transcript
Motley Fool
Biotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone?
Zacks Investment Research
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Zacks Investment Research
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Zacks Investment Research
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
Zacks Investment Research
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Zacks Investment Research
Viking Therapeutics Gears Up for Q1 Earnings: Here's What to Expect
Viking Therapeutics Gears Up for Q1 Earnings: Here's What to Expect
Zacks Investment Research
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Zacks Investment Research
TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication
TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Inovio Pharmaceuticals (INO), Elevance Health (ELV)
Tipranks
Inovio Pharmaceuticals Announces New Public Equity Offering
Tipranks
Inovio Pharmaceuticals Suspends Existing At-the-Market Stock Program
Zacks Investment Research
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate
Zacks Investment Research
SRPT Stock Surges on Promising Early Results From siRNA Programs
SRPT Stock Surges on Promising Early Results From siRNA Programs

Profile

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.